Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia

Lin Fan,1,* Yiwen You,1,* Yao Fan,2 Chong Shen,3 Yong Xue4 1Department of Pharmacy, Huai’an Third People’s Hospital, Huai’an, People’s Republic of China; 2Division of Clinical Epidemiology, Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fan L, You Y, Fan Y, Shen C, Xue Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	apolipoprotein a1 gene polymorphism dyslipidemia schizophrenia antipsychotic drug Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/29694fbb777d4505bbaa21a954b04a1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29694fbb777d4505bbaa21a954b04a1b
record_format	dspace
spelling	oai:doaj.org-article:29694fbb777d4505bbaa21a954b04a1b2021-12-02T15:40:18ZAssociation Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia1178-2021https://doaj.org/article/29694fbb777d4505bbaa21a954b04a1b2021-04-01T00:00:00Zhttps://www.dovepress.com/association-between-apoa1-gene-polymorphisms-and-antipsychotic-drug-in-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Lin Fan,1,* Yiwen You,1,* Yao Fan,2 Chong Shen,3 Yong Xue4 1Department of Pharmacy, Huai’an Third People’s Hospital, Huai’an, People’s Republic of China; 2Division of Clinical Epidemiology, Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; 3Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China; 4Department of Medical Laboratory, Huai’an Third People’s Hospital, Huai’an, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yong XueDepartment of Medical Laboratory, Huai’an Third People’s Hospital, Huai’an, People’s Republic of ChinaTel +86 13861583118Email xueyong3@126.comPurpose: Dyslipidemia frequently occurs in schizophrenia patients treated with antipsychotic drugs (APDs), especially atypical APDs. Apolipoprotein A1 (ApoA1) plays a key role in lipid metabolism. The aim of this study was to investigate whether ApoA1 gene polymorphisms are associated with APD-induced dyslipidemia in schizophrenia patients.Patients and Methods: A total of 1987 patients with schizophrenia were enrolled in this study. Serum lipid profiles were determined with a biochemistry analyzer. Genotyping for the rs5072 polymorphism of ApoA1 was performed with TaqMan assay. Logistic regression analysis was carried out to evaluate the relationship between ApoA1 gene polymorphisms and APD-induced dyslipidemia. The effects of drug classification (typical vs atypical APD) and drug regimen (monotherapy vs combination therapy) on serum lipid levels were also analyzed.Results: A significant association was found between rs5072 and triglyceride (TG) levels in the recessive model of the logistic regression analysis (adjusted odds ratio [OR]=1.50, 95% confidence interval [CI]: 1.03, 2.17; P< 0.05). TG level was significantly higher in patients treated with combination therapy (1.03 (0.71, 1.51) mmol/l) compared to monotherapy (0.93 (0.67, 1.43) mmol/l) and was also associated with sex. There were significant differences in TG levels among the three genotypes of ApoA1 rs5072 (GG, GA, and AA) in the whole study population and in patients treated with atypical APDs.Conclusion: The ApoA1 rs5072 variant is associated with dysregulated TG metabolism in schizophrenia patients treated with APDs, which may increase susceptibility to dyslipidemia.Keywords: apolipoprotein A1, gene polymorphism, dyslipidemia, schizophrenia, antipsychotic drugFan LYou YFan YShen CXue YDove Medical Pressarticleapolipoprotein a1gene polymorphismdyslipidemiaschizophreniaantipsychotic drugNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1289-1297 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	apolipoprotein a1 gene polymorphism dyslipidemia schizophrenia antipsychotic drug Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	apolipoprotein a1 gene polymorphism dyslipidemia schizophrenia antipsychotic drug Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Fan L You Y Fan Y Shen C Xue Y Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
description	Lin Fan,1,* Yiwen You,1,* Yao Fan,2 Chong Shen,3 Yong Xue4 1Department of Pharmacy, Huai’an Third People’s Hospital, Huai’an, People’s Republic of China; 2Division of Clinical Epidemiology, Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; 3Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China; 4Department of Medical Laboratory, Huai’an Third People’s Hospital, Huai’an, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yong XueDepartment of Medical Laboratory, Huai’an Third People’s Hospital, Huai’an, People’s Republic of ChinaTel +86 13861583118Email xueyong3@126.comPurpose: Dyslipidemia frequently occurs in schizophrenia patients treated with antipsychotic drugs (APDs), especially atypical APDs. Apolipoprotein A1 (ApoA1) plays a key role in lipid metabolism. The aim of this study was to investigate whether ApoA1 gene polymorphisms are associated with APD-induced dyslipidemia in schizophrenia patients.Patients and Methods: A total of 1987 patients with schizophrenia were enrolled in this study. Serum lipid profiles were determined with a biochemistry analyzer. Genotyping for the rs5072 polymorphism of ApoA1 was performed with TaqMan assay. Logistic regression analysis was carried out to evaluate the relationship between ApoA1 gene polymorphisms and APD-induced dyslipidemia. The effects of drug classification (typical vs atypical APD) and drug regimen (monotherapy vs combination therapy) on serum lipid levels were also analyzed.Results: A significant association was found between rs5072 and triglyceride (TG) levels in the recessive model of the logistic regression analysis (adjusted odds ratio [OR]=1.50, 95% confidence interval [CI]: 1.03, 2.17; P< 0.05). TG level was significantly higher in patients treated with combination therapy (1.03 (0.71, 1.51) mmol/l) compared to monotherapy (0.93 (0.67, 1.43) mmol/l) and was also associated with sex. There were significant differences in TG levels among the three genotypes of ApoA1 rs5072 (GG, GA, and AA) in the whole study population and in patients treated with atypical APDs.Conclusion: The ApoA1 rs5072 variant is associated with dysregulated TG metabolism in schizophrenia patients treated with APDs, which may increase susceptibility to dyslipidemia.Keywords: apolipoprotein A1, gene polymorphism, dyslipidemia, schizophrenia, antipsychotic drug
format	article
author	Fan L You Y Fan Y Shen C Xue Y
author_facet	Fan L You Y Fan Y Shen C Xue Y
author_sort	Fan L
title	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
title_short	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
title_full	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
title_fullStr	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
title_full_unstemmed	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
title_sort	association between apoa1 gene polymorphisms and antipsychotic drug-induced dyslipidemia in schizophrenia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/29694fbb777d4505bbaa21a954b04a1b
work_keys_str_mv	AT fanl associationbetweenapoa1genepolymorphismsandantipsychoticdruginduceddyslipidemiainschizophrenia AT youy associationbetweenapoa1genepolymorphismsandantipsychoticdruginduceddyslipidemiainschizophrenia AT fany associationbetweenapoa1genepolymorphismsandantipsychoticdruginduceddyslipidemiainschizophrenia AT shenc associationbetweenapoa1genepolymorphismsandantipsychoticdruginduceddyslipidemiainschizophrenia AT xuey associationbetweenapoa1genepolymorphismsandantipsychoticdruginduceddyslipidemiainschizophrenia
_version_	1718385862250594304

Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia

Ejemplares similares